Thalia Therapeutics Plc (AIM:THAT)

London flag London · Delayed Price · Currency is GBP · Price in GBX
0.575
0.00 (0.00%)
Apr 28, 2026, 1:46 PM GMT
53.33%
Market Cap 4.79M
Revenue (ttm) 7.07K
Net Income (ttm) -1.10M
Shares Out 832.28M
EPS (ttm) -0.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 17,500
Average Volume 2,365,414
Open 0.550
Previous Close 0.575
Day's Range 0.550 - 0.575
52-Week Range 0.350 - 1.000
Beta 0.52
RSI 62.51
Earnings Date Jun 25, 2026

About Thalia Therapeutics

Thalia Therapeutics Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom. It develops Nuvec, a silica nanoparticle delivery system, which has an irregular surface structure that traps and protects siRNA/RNA/DNA; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene. The company also engages in the development of N4 101, an orally delivered inflammation inhibitor which is in ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1979
Employees 4
Stock Exchange London Stock Exchange AIM
Ticker Symbol THAT
Full Company Profile

Financial Performance

In 2024, Thalia Therapeutics's revenue was 7,282, an increase of 272.86% compared to the previous year's 1,953. Losses were -1.06 million, -16.60% less than in 2023.

Financial Statements

News

There is no news available yet.